uniQure Narrows Loss in Fiscal Q2
uniQure (NASDAQ:QURE), a gene therapy developer focused on rare diseases, released results for the second quarter of fiscal 2025 on July 29, 2025. The headline news: the company's net loss narrowed to $0.69 per share (GAAP) in Q2 2025, ahead of analyst expectations for a GAAP loss of $0.89. Revenue for the quarter came in at $5.3 million, just below the $5.4 million expected and well down from Q2 2024 GAAP revenue of $11.1 million. However, the company ended the period with a robust cash balance, providing enough runway to fund operations into the second half of 2027. Overall, the quarter illustrated careful cost control and regulatory progress, but highlighted the ongoing need for successful clinical milestones in its core gene therapy pipeline.
Source: Analyst estimates for the quarter provided by FactSet.
uniQure (NASDAQ:QURE) develops genetic therapies for rare and serious diseases, using viral vectors to deliver corrected genetic material into patient cells. Its current lead asset is AMT-130, a gene therapy for Huntington’s disease. Huntington’s is a progressive genetic disorder that causes degeneration in nerve cells, with no cures currently available.
Source Fool.com
